Skip to content

Released Aug 13, 2024, before the open

10-Q filed Aug 13, 2024, 44 days after period end · 0001576885-24-000092

Q2 2024 · 10-Q
Revenue—
Net Income-$20.54MN/M vs Q2 2023N/M vs Q1 2024
EPS Diluted-$0.34N/M vs Q2 2023N/M vs Q1 2024
Operating Income-$24,381,000N/M
Operating Cash Flowderived-$16,545,000N/M
Free Cash Flowderived-$16,550,000N/M

What the release said

The release

Same quarter

MetricQ2 2024Q2 2023Q2 2022Q2 2021
Net Income-$20.54M-$11.61M-$10.15M-$61.36M
EPS Diluted-$0.34-$0.28-$0.25-$141.93

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Acumen Pharmaceuticals, Inc. · CIK 1576885 · Engraved from SEC EDGAR